Syno Minicircle Biotechnology Co. Ltd. (abbreviated as SynoMC) was founded by a group of returnees from USA in Aug 2016. Its team consists of established inventors of minicircle (MC) DNA and targeted delivery technologies, and seasoned biopharmaceutical specialists. The innovative and proprietary MC platform technologies are being used to develop safe, effective, convenient and affordable gene therapies for unmet medical needs. SynoMC has made significant accomplishment in R&D pipeline, research collaboration, IP rights protection and joint-venture for commercialization. SynoMC’s goal is to become a global leader of gene therapy.